- Home
- PACB vs MREO Comparison
PACB vs MREO Comparison
Compare PACB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- MREO
- Stock Information
- Founded
- PACB 2000
- MREO 2015
- Country
- PACB United States
- MREO United Kingdom
- Employees
- PACB N/A
- MREO 36
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PACB Industrials
- MREO Health Care
- Exchange
- PACB Nasdaq
- MREO Nasdaq
- Market Cap
- PACB 369.5M
- MREO 311.8M
- IPO Year
- PACB 2010
- MREO N/A
- Fundamental
- Price
- PACB $1.41
- MREO $1.97
- Analyst Decision
- PACB Buy
- MREO Strong Buy
- Analyst Count
- PACB 7
- MREO 5
- Target Price
- PACB $1.90
- MREO $7.40
- AVG Volume (30 Days)
- PACB 6.8M
- MREO 1.3M
- Earning Date
- PACB 11-06-2025
- MREO 11-11-2025
- Dividend Yield
- PACB N/A
- MREO N/A
- EPS Growth
- PACB N/A
- MREO N/A
- EPS
- PACB N/A
- MREO N/A
- Revenue
- PACB $156,110,000.00
- MREO $500,000.00
- Revenue This Year
- PACB $6.17
- MREO N/A
- Revenue Next Year
- PACB $15.63
- MREO $72.16
- P/E Ratio
- PACB N/A
- MREO N/A
- Revenue Growth
- PACB N/A
- MREO N/A
- 52 Week Low
- PACB $0.85
- MREO $1.47
- 52 Week High
- PACB $2.72
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- PACB 51.90
- MREO 56.30
- Support Level
- PACB $1.39
- MREO $1.94
- Resistance Level
- PACB $1.60
- MREO $2.12
- Average True Range (ATR)
- PACB 0.10
- MREO 0.11
- MACD
- PACB 0.02
- MREO 0.01
- Stochastic Oscillator
- PACB 48.15
- MREO 65.00
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).